Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVGH Quadrivalent Pan-Salmonella Vaccine with Alum
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GVGH Quadrivalent Pan-Salmonella Vaccine with Alum is an investigational vaccine developed by the GSK Vaccines Institute for Global Health (GVGH) to provide broad protection against invasive Salmonella diseases. It is a quadrivalent formulation targeting four major serovars: Salmonella Typhi, Salmonella Paratyphi A, Salmonella Typhimurium, and Salmonella Enteritidis. The vaccine utilizes Generalized Modules for Membrane Antigens (GMMA) technology, which involves outer membrane vesicles shed by genetically modified bacteria. This specific version is adjuvanted with aluminum hydroxide (alum) to enhance the magnitude and duration of the immune response. It is currently in Phase 1 clinical development, specifically being evaluated for safety and immunogenicity in healthy adults in Africa.
- Other names
- Pan-Salmonella-with-AlumQuadrivalent Pan-Salmonella Vaccine with Alum
02
Targets
Vi antigen (Vi capsular polysaccharide)O9 (Salmonella Enteritidis O-antigen polysaccharide)Salmonella Paratyphi A O:2 O-antigenO-antigen (Salmonella Typhimurium O-antigen polysaccharide)SseB (Secreted effector protein SseB)
Beyond the preview
Go deeper on GVGH Quadrivalent Pan-Salmonella Vaccine with Alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVGH Quadrivalent Pan-Salmonella Vaccine with Alum.